ArticleJournal of ophthalmic & vision research2025
Pilocarpine 1% for Improved Near Vision in Pseudophakic Patients.
Article in Journal of ophthalmic & vision research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of 1% pilocarpine to enhance near vision in pseudophakic patients with monofocal intraocular lens (IOL). Methods: This prospective, nonrandomized, open-label, pre-post interventional study was conducted on patients who had a history of phacoemulsification and monofocal IOL implantation without any complications at least six months before the intervention. One drop of 1% pilocarpine solution was instilled in one of the patients' eyes, and near and distance visual acuity was assessed before and 20 minutes after monocular administration of the drop. Adverse effects were monitored for 8 hours. Results: We studied54 pseudophakic eyes of 54 patients with a mean age of 55.02 Conclusion: The monocular 1% pilocarpine solution significantly improved near visual acuity among patients with pseudophakia and featured an acceptable safety profile. Although this improvement is considerable, it may not be sufficient for complete spectacle independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.